On March 5, 2025, Zyversa Therapeutics entered into a private placement agreement to sell warrants and shares for approximately $2 million, closing on March 7, 2025, to fund working capital. A special stockholder meeting on March 4, 2025, was adjourned due to lack of quorum, with proposals to be included in the upcoming Annual Meeting on June 11, 2025.